Italia markets closed

AstraZeneca PLC (AZN.ST)

Stockholm - Stockholm Prezzo in tempo reale. Valuta in SEK.
Aggiungi a portafoglio
1.110,60-1,60 (-0,14%)
Alla chiusura: 05:29PM CET

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
44 20 3749 5000
https://www.astrazeneca.com

Settore/iHealthcare
SettoreDrug Manufacturers—General
Impiegati a tempo pieno76.100

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Pascal Soriot D.V.M., M.B.A.CEO & Exec. Director5,91MN/D1959
Mr. Marc DunoyerChief Exec. Officer of Alexion3,3MN/D1952
Dr. Aradhana Sarin M.D.CFO & Exec. DirectorN/DN/D1975
Ms. Pam P. ChengEVP of Operations & Information Technology and Member of External Sustainability Advisory BoardN/DN/D1971
Mr. Thomas Kudsk LarsenHead of Investor RelationsN/DN/D1974
Mr. Jeffrey PottEVP of HR, Chief HR Officer, Gen. Counsel & Member of External Sustainability Advisory BoardN/DN/DN/D
Ms. Katarina AgeborgEVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory BoardN/DN/DN/D
Dr. Menelas Pangalos Ph.D.EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory BoardN/DN/DN/D
Dr. Ruud Dobber Ph.D.Exec. Vice-Pres of BioPharmaceuticals Bus. UnitN/DN/DN/D
Dr. Susan Mary Galbraith M.D., Ph.D.Exec. VP of Oncology R&DN/DN/D1966
Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in SEK.

Descrizione

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; Proteros biostructures GmbH to discover and develop novel small molecules. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; and Scorpion Therapeutics, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. The company was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di AstraZeneca PLC al 26 settembre 2021 è 7. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 9; diritti degli azionisti: 1; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.